News for Delcath Systems, Inc. (DCTH)

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Delcath Systems Inc (DCTH) fell 7.33% in mid-day trading on May 30. The stock reached an intraday low of $15.73, before recovering slightly to $15.8

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

H.C. Wainwright has increased its price target for Delcath Systems (DCTH) from $24 to $29, maintaining a Buy rating on the stock. This adjustment comes as Delca

Shares of Delcath Systems Inc (DCTH) fell 3.54% in mid-day trading on May 22. The stock reached an intraday low of $16.56, before recovering slightly to $16.6

Delcath Systems, Inc. (Nasdaq: DCTH) (”œDelcath” or the ”œCompany”), an interventional oncology company focused on the treatment of primary and metastati

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Delcath Systems (DCTH) stock gains as the company projects over 150% revenue growth in 2025 amid Medicaid market access plans. Read more here.

Delcath Systems, Inc. (DCTH) to attend the Craig-Hallum 22nd Annual Investor Conference on May 28, 2025. The company's HEPZATO KIT is approved in the U.

Delcath Systems, Inc. (Nasdaq: DCTH) (the ”œCompany” or ”œDelcath”), an interventional oncology company focused on the treatment of primary and metastati

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Delcath Systems I

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NDCTH.OQ - Delcath Systems IncQ1 2025 Delcath Systems Inc Earnings CallMay 08, 2025 / 12:30PM G

The following slide deck was published by Delcath Systems, Inc.

Discover key insights from Delcath Systems' Q1 2025 earnings call. Learn about revenue growth, HEPZATO's U.S.

Delcath Systems, Inc. (NASDAQ:DCTH) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsDavid Hoffman - General Counsel, Corporate...

Delcath Systems (DCTH) delivered earnings and revenue surprises of -70% and 9.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems (DCTH) has received clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial assessing Hepzato. This development f

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday. Shares of Eagle Financial Services, Inc. EFSI fell sha...